A comparative study between condensed polytetrafluoroethylene mesh versus other composite meshes in Endo-laparoscopic ventral herniorrhaphy by Meredeth Chin, James Lee Wai Kit, Sujith Wijerathne, Avelyn Aw, Daryl Chia Kai Ann, Sean Lee Kien Fatt, Tharun Ragupathi, Harry Ng Ho Man, Davide Lomanto

“…Patient demographics, Hernia Characteristics, perioperative events, postoperative results and complications were documented and analysed. …”
Get full text

Adherence to vaccination against SARS-CoV-2 and vaccine safety in patients with immunoglobulin G4-related disease by Linda Mastromanno, Federico Giardina, Angelica Gattamelata, Serena Colafrancesco, Simona Truglia, Francesca Romana Spinelli, Edoardo Simoncelli, Bruno Lucchino, Fabrizio Conti, Roberta Priori

“…To assess the adherence to the vaccination campaign against SARS-CoV-2 in patients with immunoglobulin-G4-related disease (IgG4-RD) and to evaluate the development of local and systemic adverse events (AEs) following vaccination. Additionally, to investigate the rate and outcome of SARS-CoV-2 infection in IgG4-RD patients. …”
Get full text

Role of the Bronchoalveolar Lavage in Noncritically Ill Patients during the SARS-CoV-2 Epidemic by Olivier Taton, Emmanuelle Papleux, Benjamin Bondue, Christiane Knoop, Sébastien Van Laethem, Alain Bauler, Delphine Martiny, Isabel Montesinos, Marie-Luce Delforge, Kahina Elmaouhab, Dimitri Leduc

“…No significant adverse event was noted for patients or health-care staff. …”
Get full text

Host-Induced Gene Silencing of the <i>Aspergillus flavus O</i>-Methyl Transferase Gene Enhanced Maize Aflatoxin Resistance by Olanike Omolehin, Yenjit Raruang, Dongfang Hu, Zhu-Qiang Han, Surassawadee Promyou, Robert L. Brown, Qijian Wei, Kanniah Rajasekaran, Jeffrey W. Cary, Kan Wang, Dan Jeffers, Zhi-Yuan Chen

“…Among the six transformation events that were positive for containing the <i>omtA</i> transgene, OmtA-6 and OmtA-10 were self-pollinated from T1 to T4, and OmtA-7 and OmtA-12 to the T6 generation. …”
Get full text

Unleashing the potential of geostationary satellite observations in air quality forecasting through artificial intelligence techniques by C. Zhang, X. Niu, H. Wu, Z. Ding, K. L. Chan, J. Kim, T. Wagner, C. Liu, C. Liu, C. Liu

“…Our findings demonstrate the significant potential of geostationary satellite observations in artificial-intelligence-based air quality forecasting, with implications for early warning of air pollution events and human health exposure.</p>…”
Get full text

Life history, reproductive, and demographic parameters for bottlenose dolphins (Tursiops truncatus) in Sarasota Bay, Florida by Randall S. Wells, Aleta A. Hohn, Michael D. Scott, Jay C. Sweeney, Forrest I. Townsend, Jason B. Allen, Aaron A. Barleycorn, Katherine A. McHugh, Kim Bassos-Hull, Gretchen N. Lovewell, Deborah A. Duffield, Cynthia R. Smith, A. Blair Irvine

“…Periods of increased loss rates were related to environmental events, and factors that may be important to long-term population resilience were suggested.…”
Get full text

Impacts of Sandstorms on Chemistries of Ambient PAHs in a Small City in North China by Zhiyong Li, Zhen Zhai, Jixiang Liu, Lan Chen, Zhuangzhuang Ren, Chen Liu, Ziyi Zhan, Ziyuan Yue, Wenjia Zhu, Jihong Wei, Huiying Gao, Songtao Guo

“…Abstract Sandstorm events frequently perplex northern China, addressing the people’s concern due to subsequent increases in the toxicity and carcinogenicity of PM2.5-bound PAHs (PB-PAHs) in receptor area of sand dust. …”
Get full text

A Phase I/II Study of Ultra-Hypofractionated Carbon-ion Radiation therapy for Low- and Intermediate-Risk Localized Prostate Cancer by Noriyuki Okonogi, MD, PhD, Hiroshi Tsuji, MD, PhD, Kana Kobayashi, MD, PhD, Mio Nakajima, MD, PhD, Shuri Aoki, MD, PhD, Takanobu Utsumi, MD, PhD, Hiroyoshi Suzuki, MD, PhD, Koichiro Akakura, MD, PhD, Tomohiko Ichikawa, MD, PhD, Hitoshi Ishikawa, MD, PhD

“…Neither group experienced grade 3 or higher GI or GU adverse events; therefore, no dose-limiting toxicities were observed. …”
Get full text

Treatment of Helicobacter pylori infection: mainstream and innovations (Review of the literature and Russian gastroenterological association Advisory council resolution, May 19, 20... by V. T. Ivashkin, I. V. Mayev, T. L. Lapina, A. A. Sheptulin, A. S. Trukhmanov, R. A. Abdulkhakov, S. A. Alekseyenko, N. N. Dekhnich, R. S. Kozlov, I. L. Klyaritskaya, S. A. Kurilovich, M. F. Osipenko, V. I. Simanenkov, I. B. Khlynov

“…Significant decrease of adverse events rate at H. pylori eradication treatment is reached at combined prescription of probiotics. …”
Get full text

Early sST2 Liberation after Implantation of a Left Ventricular Assist Device in Patients with Advanced Heart Failure by Philipp Opfermann, Elisabeth Simader, Alessia Felli, Michele Bevilacqua, Caroline Holaubek, Martin Dworschak, Mohamed Mouhieddine, Daniel Zimpfer, Jan Hendrik Ankersmit, Barbara Steinlechner

“…The frequency of adverse events remains high. We examined the early expression of circulating soluble ST2 (sST2), a biomarker with immunosuppressive and profibrotic activity, and assessed the risk of death at 1 year in patients receiving LVAD implant. …”
Get full text

Risk Factors of Bacteremia following Multiple Traumas by Hak-Jae Lee, Eol Choi, Nak-Joon Choi, Hyun-Woo Sun, Jae-Suk Lee, Jeong-Woo Lee, Tae-Yoon Kim, Yoon-Joong Jung, Suk-Kyung Hong

“…Thirty-four patients of 859 (4%) developed bacteremia during their hospital stay: 4 (11.8%) developed EOB, 26 (76.4%) LOB, and 4 (11.8%) patients developed both of them. Sixty events of bacteremia happened to these patients: 9 (15.0%) EOB and 51 (85.0%) LOB. …”
Get full text

Neoadjuvant pyrotinib and trastuzumab in HER2-positive breast cancer with no early response (NeoPaTHer): efficacy, safety and biomarker analysis of a prospective, multicentre, resp... by Fei Wang, Yongjiu Wang, Bin Xiong, Zhenlin Yang, Jingfen Wang, Yumin Yao, Lixiang Yu, Qinye Fu, Liang Li, Qiang Zhang, Chao Zheng, Shuya Huang, Liyuan Liu, Chun Liu, Huaibo Sun, Beibei Mao, Dong-Xu Liu, Zhigang Yu

“…Multivariable logistic regression analyses demonstrated comparable odds of achieving tpCR between cohorts A and C (odds ratio = 1.04, 95% CI: 0.40–2.70). No new adverse events were observed with the addition of pyrotinib. …”
Get full text

Acceptance and safety of the RSV-preventive treatment of newborns with nirsevimab in the maternity department: a prospective longitudinal cohort study in FranceResearch in context by Charlotte Ocana de Sentuary, Clara Testard, Marion Lagrée, Maxime Leroy, Lisa Gasnier, Alicia Enes-Dias, Constance Leruste, Diariatou Diallo, Michael Génin, Thameur Rakza, François Dubos

“…The occurrence of adverse events (AEs) 2 h after nirsevimab treatment and 7, 14 and 30 days after discharge was documented by the mother. …”
Get full text

A multicenter, randomized, double-blind, placebo-controlled phase 3 study of Socazolimab or placebo combined with carboplatin and etoposide in the first-line treatment of extensive... by Zhiwei Chen, Jianhua Chen, Dingzhi Huang, Wei Zhang, Lin Wu, Tienan Yi, Qiming Wang, Liang Han, Liping Tan, Yinyin Li, Zhihong Zhang, Na Li, Jie li, Tongmei Zhang, Ying Hu, Hongmei Sun, Youhua Wu, Zhiyong He, Runxiang Yang, Peng Cheng, Xingya Li, Jianhua Shi, Guohua Yu, Daiyuan Ma, Benjamin Xiaoyi Li, Xiangrong Dai, Michael Wong, Yujie Li, Xiaohui Yu, Shun Lu, for the Socazolimab Study Group

“…The median progression free survival (PFS) was 5.55 months in the socazolimab plus EC group, prolonging disease progression or death by nearly 1.2 months (5.55 months vs 4.37 months, hazard ratio for progression or death, 0.569; 95% CI, 0.457–0.708; p < 0.0001). 200 (80.3%) patients in the socazolimab plus EC group experienced ≥ grade 3 treatment-related adverse events and 187 (75.7%) patients occurred in the placebo plus EC group. …”
Get full text

Predictors of Recurrence After Curative Surgery for Stage I Colon Cancer: Retrospective Cohort Analysis of the Italian Society of Surgical Oncology Colorectal Cancer Network Collab... by Giulia Turri, MD, Luigi Martinelli, MD, Daniela Rega, MD, Nicolò Tamini, MD, Lucia Paiano, MD, Simona Deidda, MD, QuocRiccardo Bao, MD, Laura Lorenzon, MD, PhD, Raffaele De Luca, MD, Caterina Foppa, MD, PhD, Valentina Mari, MD, Giovanni Taffurelli, MD, Arcangelo Picciariello, MD, PhD, Patrizia Marsanic, MD, Leandro Siragusa, MD, Francesco Bagolini, MD, Riccardo Nascimbeni, MD, Gianluca Rizzo, MD, PhD, Sara Vertaldi, MD, Michele Zuolo, MD, Giorgio Bianchi, MD, Lisa Marie Rorato, MD, Rossella Reddavid, MD, PhD, Gaetano Gallo, MD, PhD, Lorenzo Crepaz, MD, Alberto Di Leo, MD, Mario Trompetto, MD, Enrico Potenza, MD, Mauro Santarelli, MD, Nicola de’Angelis, MD, PhD, Francesco Ciarleglio, MD, Marco Milone, MD, PhD, Claudio Coco, MD, Guido Alberto Tiberio, MD, Gabriele Anania, MD, Giuseppe S. Sica, MD, PhD, Andrea Muratore, MD, Donato Francesco Altomare, MD, Isacco Montroni, MD, PhD, Maurizio De Luca, MD, Antonino Spinelli, MD, PhD, Michele Simone, MD, Roberto Persiani, MD, Gaya Spolverato, MD, Angelo Restivo, MD, Nicolò de Manzini, MD, Marco Braga, MD, Paolo Delrio, MD, Giuseppe Verlato, MD, PhD, Corrado Pedrazzani, MD, Adriana Gioia, Cristina Vacca, Dario Parini, Giovanni Tomasicchio, Marcello Calabrò, Bruno Sensi, Filomena Misuriello, Carlo Alberto Schena, Silvia Picotto

“…Eighty patients developed cancer recurrence (5.0%), of which 90% was systemic relapse. The event was more frequent in pT2 (6.0% vs 3.2%, P = 0.013), male patients (6.1% vs 3.6%, P = 0.021), in the presence of lymphovascular invasion (7.2% vs 3.6%, P = 0.01), and in cases of partial resection (11.1% vs 4.6%, P = 0.011). …”
Get full text

Evaluating the radiosensitivity of the oral microbiome to predict radiation-induced mucositis in head and neck cancer patients: A prospective trial by Andreas R. Thomsen, Elsa Beatriz Monroy Ordonez, Michael Henke, Benedikt Luka, Jörg Sahlmann, Henning Schäfer, Vivek Verma, Nadine Schlueter, Anca-Ligia Grosu, Tanja Sprave

“…No patient experienced a grade ≥ 4 event. There was a correlation between the cell spreading assay area and grade 3 OM (p < 0.05), equivalent to approximately 0.5 Gy dose. …”
Get full text

A stratified two-stage tumor molecular profiling algorithm to identify clinically actionable molecular alterations in pancreatic cancer☆ by S. Hussung, D. Akhoundova, C. Pistoni, D. Lenggenhager, A. Töpfer, C. Pauli, B. Pestalozzi, C. Britschgi, M. Zoche, M. Rechsteiner, H. Moch, A. Weber, R. Fritsch

“…Based on pre-specified events (KRAS wild type, mismatch repair deficiency, molecular tumor board recommendation), subsequent comprehensive molecular testing was carried out (stage 2). …”
Get full text

Moscatilin inhibits vascular calcification by activating IL13RA2-dependent inhibition of STAT3 and attenuating the WNT3/β-catenin signalling pathway by Tingting Zhang, Mengmeng Zhu, Jialing Ma, Zhenghong Liu, Zhidan Zhang, Meijie Chen, Yaping Zhao, Huaxin Li, Shengnan Wang, Xiaoning Wei, Wenwen Zhang, Xiaoxiao Yang, Peter J. Little, Danielle Kamato, Hao Hu, Yajun Duan, Baotong Zhang, Jianbo Xiao, Suowen Xu, Yuanli Chen

“…Introduction: Vascular calcification, a devastating vascular complication accompanying atherosclerotic cardiovascular disease and chronic kidney disease, increases the incidence of adverse cardiovascular events and compromises the efficacy of vascular interventions. …”
Get full text

Feasibility and safety evaluation of ultra-remote robot-assisted laparoscopic hysterectomy by Juyuan Huang, Li'an Li, Jing Cheng, Jing Liao, Yurou Chen, Yi Peng, Sha Wang, Qiongyan Zou, Guoyan Zhao, Wei Zhao, Mengya You, Jingying Yang, Yan Xiong, Kunxian Zhang, Chang Chen, Jiaqiang Xiong, Haotong Guan, Renjie Liu, Peng Zhou, Wuyi Zhao, Yangyang Dong, Xiuli Sun, Sichen Liang, Wei Zhang, Jianliu Wang, Yuanguang Meng

“…The bidirectional latency during the operation was around 19 ​ms, with no adverse events related to the robot or the network. The patient recovered well postoperatively and was discharged on the fourth day with no postoperative complications. …”
Get full text

Phase Ib open-label, multicenter study of pixatimod, an activator of TLR9, in combination with nivolumab in subjects with microsatellite-stable metastatic colorectal cancer, metast... by Matthew Burge, David Goldstein, Andrew Haydon, Nick Pavlakis, Charlotte Lemech, Edward Hammond, Darryn Bampton, Keith Dredge, Michael P Brown, Andrew Clouston, Nigel J Waterhouse, Amanda C Stanley, Lucie Leveque-El Mouttie, Grace M Chojnowski

“…Twenty-one grade 3–5 treatment-related adverse events were reported in 12 participants (21%); one participant receiving 50 mg pixatimod/nivolumab had a treatment-related grade 5 AE. …”
Get full text